CYP1A1 rs4646421: What Your Genotype Means
The rs4646421 variant is a genetic change located within the CYP1A1 gene, which encodes an enzyme responsible for metabolizing various foreign substances. Research has investigated its potential role in influencing individual susceptibility to certain cancers, though the evidence remains limited and often context-dependent.
What each genotype means
Typical CYP1A1 activity
This genotype represents the most common form of the CYP1A1 gene in many populations. Research into this variant often focuses on how it influences the metabolism of environmental toxins and certain medications, but the clinical significance of this specific genotype remains limited and is not a diagnostic indicator of health outcomes.
This is the most frequent genotype observed in global populations.
Heterozygous variant profile
Carrying one copy of the T allele may influence the activity of the CYP1A1 enzyme, which is involved in processing xenobiotics and certain therapeutic drugs. Studies have explored associations between CYP1A1 variants and cancer risk, but evidence is mixed and often depends on environmental factors like smoking status; please discuss any concerns regarding medication metabolism with your clinician or pharmacist.
This genotype is common, with the T allele appearing at a frequency of approximately 27% in many studied populations.
Variant genotype profile
This genotype involves two copies of the T allele, which has been investigated for its potential role in altering the metabolism of environmental compounds and certain medications. While some research suggests links between CYP1A1 variants and susceptibility to specific health conditions, the evidence is limited and inconsistent across different ancestries; always consult your healthcare provider regarding personalized medication management.
This genotype is less common than the C/C or C/T genotypes, occurring in a smaller subset of the population.
Understanding the rs4646421 Variant
The rs4646421 variant is a single nucleotide polymorphism (SNP) situated within the CYP1A1 gene on chromosome 15. In genomics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in a region of the gene that may influence how the body processes external chemicals, known as xenobiotics. Because this variant is common in many populations, it has been the subject of numerous studies aiming to understand if it contributes to differences in how people metabolize environmental toxins or medications. It is important to note that while this variant is frequently studied, its presence does not inherently indicate a health condition, and scientific findings regarding its functional impact are often mixed or require further validation.
The Role of the CYP1A1 Gene
The CYP1A1 gene provides instructions for making a member of the cytochrome P450 superfamily of enzymes. These enzymes are primarily known for their role in Phase I metabolism, where they chemically modify substances to make them easier for the body to eliminate. CYP1A1 is particularly notable for its ability to metabolize polycyclic aromatic hydrocarbons, which are chemicals found in tobacco smoke and certain environmental pollutants. By modifying these substances, the enzyme can sometimes convert them into reactive intermediates that may interact with DNA. Because of this, researchers have long hypothesized that variations in the CYP1A1 gene might influence an individual's risk of developing cancers related to chemical exposure. However, the enzyme's activity is complex and influenced by many factors, including diet, lifestyle, and the presence of other genetic variations.
Research Associations and Evidence Strength
Scientific literature has explored the association between rs4646421 and various health outcomes, most notably cancer susceptibility. Some studies have suggested that certain genotypes might be linked to a higher risk of lung or other cancers, particularly in the context of smoking or environmental exposure. However, the evidence strength for these associations is considered limited. Results across different studies are often contradictory, with some populations showing an association while others do not. This inconsistency is common in genetic research, as the effect of a single SNP is often small and can be masked by other genetic or environmental factors. Consequently, rs4646421 is not currently used as a definitive clinical marker for predicting disease risk, and it should not be interpreted as a diagnostic tool for any medical condition.
Population Frequency
The rs4646421 variant is considered a common genetic variation, meaning it is found at significant frequencies across many different human populations. Because it is common, it is frequently observed in large-scale genomic databases. However, the exact frequency of the specific alleles can vary significantly depending on ancestral background. Researchers often look at these frequency differences to understand the evolutionary history of the gene and to ensure that genetic studies are representative of diverse groups. If you are interested in how common this variant is within your specific ancestral group, public databases like gnomAD provide detailed frequency data based on large cohorts. Understanding that this is a common variant helps contextualize its role as a normal part of human genetic diversity rather than a rare mutation.
What You Can Do With This Information
Learning about your genetic variants can be an educational experience, but it is important to approach this information with a clear understanding of its limitations. Because the evidence linking rs4646421 to specific health outcomes is limited and inconsistent, this information is not currently actionable for medical decision-making. You cannot use this genotype to predict your personal risk of disease or to determine how you will respond to specific medications. If you have questions about your health, your family history of cancer, or how your body processes medications, the best course of action is to consult with a qualified healthcare provider or a genetic counselor. They can help you interpret your health information in the context of your overall medical history and provide guidance that is tailored to your specific needs.
How common is this variant?
The rs4646421 variant is common across global populations, though specific allele frequencies vary by ancestry.
Frequently asked questions
Is rs4646421 a cause of cancer?
No, rs4646421 is not a cause of cancer. While some research has investigated its potential association with cancer susceptibility, the evidence is limited and inconsistent, and it is not considered a diagnostic marker.
Should I change my medication based on this variant?
No. You should never change your medication or dosing based on genetic information without consulting your clinician or pharmacist. Genetic variants are only one of many factors that influence how your body processes drugs.
Where can I find more information about CYP1A1?
You can find reliable information about the CYP1A1 gene on resources like MedlinePlus Genetics or the NCBI Gene database. These sites provide comprehensive summaries of gene function and related research.
Why do studies on this variant show different results?
Genetic studies often show different results due to differences in study design, the ancestral backgrounds of the participants, and environmental factors like smoking or diet. These variables can influence how a genetic variant affects health.
Sources & further reading
Educational information only, last refreshed 9/30/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4646421?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP1A1
Intergenic variant near CYP1A1/CYP1A2 that regulates CYP1A2 activity, altering caffeine clearance and associated cardiovascular traits.
This variant in the CYP1A1 gene is associated with the development of pigmented spots on the cheeks.
An intronic regulatory polymorphism in CYP1A1 that modifies phase I xenobiotic and photoproduct metabolizing efficiency in cutaneous keratinocytes under ultraviolet radiation.